EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse

Cyrille Touzeau iD, Xavier Leleu iD, Mourad Tiab, Margaret Macro, Aurore Perrot, Julie Gay, Carine Chateleix, Stéphane Moreau, Lionel Karlin, Caroline Jacquet, Salomon Manier iD, Cyrille Hulin iD und 14 weitere

British Journal of Haematology · 2025-05 · 206 (5) · 1366-1372

DOI: 10.1111/bjh.19978 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 05.01.2025. Verfasst von Cyrille Touzeau und 25 weiteren Autor:innen. Beteiligte Einrichtung: Service d'hématologie, Centre Hospitalo-Universitaire, Nantes, France. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bristol Myers Squibb Foundation, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most transplant‐ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti‐CD38 monoclonal antibody at first relapse and represent a difficult‐to‐treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.6 mg on day 1–21), ixazomib (3 mg on day 1, 8, 15) and dexamethasone (20 mg on day 1, 8, 15, 22 on cycle 1–2 and 10 mg on day 1, 8, 15, 22 on cycle 3–6) (28‐day cycle) until disease progression. Median age was 76; 50% patients were frail according to the International Myeloma Working Group frailty score; 74% and 37% were refractory to lenalidomide and daratumumab respectively. With a median follow‐up of 14 months, the overall response rate was 64%, including 36% very good partial response or better. The 12‐month progression‐free survival, duration of response and overall survival were 52%, 76% and 86% respectively. The most common (46%) grade 3–4 toxicity was neutropenia. Non‐haematological adverse events were mostly grade 1 or 2. Overall, I2D demonstrated a favourable risk–benefit profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansBoron CompoundsAgedGlycineDexamethasoneMaleFemaleAged, 80 and overThalidomideRecurrence

Stichwörter der Autor:innen

elderlyiberdomideixazomibmyeloma

Substanzen

ixazomibBoron CompoundsGlycineDexamethasoneThalidomide

Autor:innen und Institutionen

  • Service d'hématologie, Centre Hospitalo-Universitaire, Nantes, France.
  • CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
  • Site de Recherche Intégrée sur le Cancer (SIRIC) « ILIAD », INCA-DGOS-Inserm_12558, Nantes, France.
  • Service d'hématologie, Centre Hospitalo-Universitaire, Université de Poitiers, Poitiers, France.
  • Service d'hématologie, Centre Hospitalier Departmental, La Roche sur Yon, France.
  • Service d'hématologie, Centre Hospitalo-Universitaire, Caen, France.

ORCID-Profile: Cyrille Touzeau, Xavier Leleu, Salomon Manier, Cyrille Hulin, Thomas Chalopin, Mohamad Mohty, Jill Corre, Philippe Moreau

Förderung

  • NCI NIH HHS
  • Bristol Myers Squibb Foundation
  • Takeda Pharmaceutical Company

Zitieren

APA

Touzeau, C., Leleu, X., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., Manier, S., Hulin, C., Decaux, O., Richez, V., Chalopin, T., Mohty, M., Orsini-Piocelle, F., Caillot, D., Sonntag, C., …, & Moreau, P. (2025). Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse. British Journal of Haematology, 206(5), 1366-1372. https://doi.org/10.1111/bjh.19978

Vancouver

Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, et al. Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse. British Journal of Haematology. 2025;206(5):1366-1372. doi:10.1111/bjh.19978

BibTeX
@article{Touzeau2025,
  author = {Touzeau, Cyrille and Leleu, Xavier and Tiab, Mourad and Macro, Margaret and Perrot, Aurore and Gay, Julie and Chateleix, Carine and Moreau, Stéphane and Karlin, Lionel and Jacquet, Caroline and Manier, Salomon and Hulin, Cyrille and Decaux, Olivier and Richez, Valentine and Chalopin, Thomas and Mohty, Mohamad and Orsini-Piocelle, Frédérique and Caillot, Denis and Sonntag, Cécile and Vignon, Marguerite and Bobin, Arthur and Avet-Loiseau, Hervé and Jobert, Alexandra and Planche, Lucie and Corre, Jill and Moreau, Philippe},
  title = {Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse},
  journal = {British Journal of Haematology},
  year = {2025},
  volume = {206},
  number = {5},
  pages = {1366--1372},
  doi = {10.1111/bjh.19978}
}
Kostenlos starten →